Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/42205
Title: The possible management of hypertensive patients infected with COVID-19 through the use of Aliskiren
Authors: Oliveira, Gabriel Melo de
Rossi, Maria Inês Doria
Affilliation: Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Ciência e Tecnologia em Biomodelos. Rio de Janeiro, RJ, Brasil.
Abstract: In late 2019, a novel corona virus (COVID-19) was identified in Wuhan, a city in the Hubei province of China. COVID-19 rapidly spread and led to an outbreak in China and then became a global health emergency. Human pathogenic coronavirus bind to their target cells through angiotensin-converting enzyme 2 (ACE2). The expression of ACE2 is substantially increased in hypertension patients and with type 1 or type 2 diabetes. Hypertension is also treated with ACE inhibitors and ARBs, which results in an upregulation of ACE2.We therefore hypothesis that hypertension and diabetes treatment with ACE2-stimulating drugs increases the risk of developing severe and fatal COVID-19. Therefore, we propose for COVID-19 patients to prevent ANG I and II formation by direct blockade of renin with the specific inhibitor called Aliskiren. The aliskiren acts as a renin inhibitor, which blocks the conversion of angiotensinogen to ANG I. Hence, blood pressure is reduce by decreasing the amount of ANG II to reach the AT1 receptor, thereby causing a decrease ACE2 released. Through the respective review, we hope to contribute to the treatment of patients infected with COVID-19, especially hypertensive patients.
Keywords: COVID-19
Possible management
Hypertensive patients
Infection
Use of Aliskiren
keywords: COVID-19
Pacientes hipertensos
Manejo
Infecção
Uso de Aliskiren
Issue Date: 2020
Publisher: Scholars Central
Citation: OLIVEIRA, Gabriel Melo de; ROSSI, Maria Inês Doria. The possible management of hypertensive patients infected with COVID-19 through the use of Aliskiren. Nephrology and Renal Diseases, v. 5, p. 1-5, May 2020.
DOI: 10.15761/NRD.1000165
ISSN: 2399-908X
Copyright: open access
Appears in Collections:ICTB - Artigos de Periódicos
IOC - Artigos de Periódicos
Files in This Item:
File Description SizeFormat 
GabrielMOliveira_MariaIDRossi_IOC_2020.pdf283.45 kBAdobe PDFView/Open



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.